A STUDY ON COST EFFECTIVENESS ANALYSIS OF DRUGS USED IN THE TREATMENT OF STROKE AT TERITARY CARE HOSPITAL-A REAL WORLD DATA

SUBASHINI R.; KAVIPRIYADHARSHINI V.; NANDHINIPRIYA S.; NILOFARNISHA M.; PREETHA K.; PUNITHA JINISHA R.

doi:10.22159/ijcpr.2025v17i3.55065

Authors

SUBASHINI R. Head of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tiruchengode, the Tamil Nadu Dr. M. G. R. Medical University, TamilNadu, India https://orcid.org/0000-0003-2825-358X
KAVIPRIYADHARSHINI V. Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tiruchengode, the TamilNadu Dr. M. G. R. Medical University, TamilNadu, India
NANDHINIPRIYA S. Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tiruchengode, the TamilNadu Dr. M. G. R. Medical University, TamilNadu, India
NILOFARNISHA M. Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tiruchengode, the TamilNadu Dr. M. G. R. Medical University, TamilNadu, India
PREETHA K. Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tiruchengode, the TamilNadu Dr. M. G. R. Medical University, TamilNadu, India
PUNITHA JINISHA R. Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tiruchengode, the TamilNadu Dr. M. G. R. Medical University, TamilNadu, India

DOI:

https://doi.org/10.22159/ijcpr.2025v17i3.55065

Keywords:

Cost effectiveness analysis, SSQOL, Cost of illness, Stroke, Direct cost, Indirect cost

Abstract

Objective: This study aims to assess the cost effectiveness of drugs used in stroke treatment within tertiary care hospital, providing evidence-based insights for more efficient resource allocation and better healthcare decision-making.

Methods: The Prospective observational study was conducted from December 2024 to March 2025 to analyse the cost effectiveness and evaluate the quality life including patient-reported outcomes and medical records, quality of life measures, healthcare resource utilisation and direct/indirect costs. Data collection utilized the SS-QOL Questionnaire for QOL assessment. GraphPad Prism was employed for data analysis, utilising paired t-tests and 95% Confidence intervals were calculated.

Results: Direct healthcare expenses include a Medication fee of Rs.1754, transportation fees of Rs.42, food fees of Rs.154.6, consultation fees of Rs.522.2. Indirect costs involve patients and caretakers loss of productivity (LOP) at Rs. 876.2 and Rs.766.7 respectively. Effective cost management in healthcare is crucial.

Conclusion: Ischemic stroke has a profound impact on quality of life, resulting the significant disability, cognitive impairment and emotional distress. In this context, cost effectiveness analysis is crucial to inform healthcare decision making resource allocation. This study has provided the comprehensive cost effectiveness analysis of drugs used in the treatment of stroke.

Downloads

Download data is not yet available.

References

Warburton E, Alawneh JA, Clatworthy PL, Morris RS. Stroke management. BMJ Clin Evid. 2011 Jun 9;2011:0201. PMID 21658301, PMCID PMC3217648.

Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Jul;44(7):2064-89. doi: 10.1161/STR.0b013e318296aeca, PMID 23652265.

Hedau VN, Patil T. Mounting stroke crisis in India: a systematic review. Cureus. 2024 Mar 27;16(3):e57058. doi: 10.7759/cureus.57058, PMID 38681344, PMCID PMC11052531.

Vale L, Thomas R, MacLennan G, Grimshaw J. Systematic review of economic evaluations and cost analyses of guideline implementation strategies. Eur J Health Econ. 2007 Jun;8(2):111-21. doi: 10.1007/s10198-007-0043-8, PMID 17347844.

Saceleanu VM, Toader C, Ples H, Covache Busuioc RA, Costin HP, Bratu BG. Integrative approaches in acute ischemic stroke: from symptom recognition to future innovations. Biomedicines. 2023 Sep 23;11(10):2617. doi: 10.3390/biomedicines11102617, PMID 37892991.

Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ. 2000 May 13;320(7245):1335. doi: 10.1136/bmj.320.7245.1335, PMID 10807635.

Rai M, Goyal R. Pharmacoeconomics in healthcare. In: Pharmaceutical medicine and translational clinical research. Amsterdam: Elsevier; 2018 Jan 1. p. 465-72. doi: 10.1016/B978-0-12-802103-3.00034-1.

Robinson R. Cost-utility analysis. BMJ. 1993 Oct 2;307(6908):859-62. doi: 10.1136/bmj.307.6908.859, PMID 8401133.

Bang H, Zhao H. Cost effectiveness analysis: a proposal of new reporting standards in statistical analysis. J Biopharm Stat. 2014 Mar 4;24(2):443-60. doi: 10.1080/10543406.2013.860157, PMID 24605979.

Legris N, Devilliers H, Daumas A, Carnet D, Charpy JP, Bastable P. French validation of the stroke specific quality of life scale (SS-QOL). Neuro Rehabilitation. 2018 Jan 30;42(1):17-27. doi: 10.3233/NRE-172178, PMID 29400672.